Medical devices, healthcare technology and the business of care
PMA approval · P160021

GORE VIABAHN VBX BALLOON EXPANDABLE ENDOPROSTHESIS

W. L. Gore & Associates, Inc. · Decision date Jan 27, 2017

MEDTECHLEDGER EXPLANATIONP160021

What did the FDA approve?

The FDA approved the GORE VIABAHN VBX Balloon Expandable Endoprosthesis for treating de novo or restenotic lesions in iliac arteries. The stated reference vessel diameters range from 5 mm to 13 mm, with lesion lengths up to 110 mm, including lesions at the aortic bifurcation.

This record is an original PMA approval, not a supplement or manufacturing notice. The statement describes the approved indication as reported by the FDA; it does not independently establish safety or clinical effectiveness. No supplement type or supplement reason is supplied.

FDA approval order statement

Approval for the GORE VIABAHN VBX Balloon Expandable Endoprosthesis is indicated for the treatment of de novo or restenotic lesions found in iliac arteries with reference vessel diameters ranging from 5mm - 13mm and lesion lengths up to 110mm, including lesions at the aortic bifurcation.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Jan 27, 2017

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P160021
Regulatory pathway
Premarket approval application
Product code
PRL
Decision code
APPR
Decision date
Jan 27, 2017
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Iliac covered stent, arterial.

Product code
PRL
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P160021 received

    Application receipt date recorded by FDA.

  2. P160021 · FDA decision

    APPR

  3. P160021/S051 · Related supplement

    GORE VIABAHN VBX Balloon Expandable Endoprosthesis

Timeline entries are records held by MedtechLedger for P160021. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160021

Product / regulatory recordCompanyPathwayDecision dateSource
W. L. Gore & Associates, Inc.PMA supplementOct 8, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

W. L. Gore & Associates, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3250 W. Kiltie Ln., Flagstaff, AZ, 86005

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records